Bio-Rad Laboratories Inc(BIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | 45.09 | EPS (ttm) | 8.25 | Insider Own | 33.25% | Shs Outstand | 21.7M | Perf Week | 0.6% |
| Market Cap | 9.96B | Forward P/E | 36.32 | EPS next Y | 5.1% | Insider Trans | -0.01% | Shs Float | 17.9M | Perf Month | 4.67% |
| Enterprise Value | 9.71B | PEG | 7.18 | EPS next Q | 2.23 | Inst Own | 72.04% | Short Float | 6.15% | Perf Quarter | 11.19% |
| Income | 0.22B | P/S | 3.85 | EPS this Y | -1.73% | Inst Trans | -7.02% | Short Ratio | 4.31 | Perf Half Y | 45.07% |
| Sales | 2.59B | P/B | 1.39 | EPS next 5Y | 5.06% | ROA | 2.17% | Short Interest | 1.10M | Perf YTD | 22.84% |
| Book/sh | 268.3 | P/C | 6.15 | EPS past 3/5Y | - -26.08% | ROE | 3.11% | 52W High | -6.07% ($396.23) | Perf Year | 22.18% |
| Cash/sh | 60.52 | P/FCF | 28.21 | Sales past 3/5Y | -2.68% 0.29% | ROIC | 2.74% | 52W Low | 57.22% ($236.73) | Perf 3Y | 38.17% |
| Dividend Est. | - | EV/EBITDA | 21.94 | EPS Y/Y TTM | -29.25% | Gross Margin | 51.86% | Volatility(W/M) | 2.91% 3.38% | Perf 5Y | -53.17% |
| Dividend TTM | - | EV/Sales | 3.75 | Sales Y/Y TTM | 1.37% | Oper. Margin | 9.08% | ATR (14) | 11.71 | Perf 10Y | 136.08% |
| Dividend Ex-Date | - | Quick Ratio | 2.33 | EPS Q/Q | 18.67% | Profit Margin | 8.59% | RSI (14) | 51.56 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.14 | Sales Q/Q | -0.09% | SMA20 | 1.29% ($367.44) | Beta | 1.06 | Target Price | $362.5 |
| Payout | - | Debt/Eq | 0.19 | Earnings | 2026/11/4 | SMA50 | -0.7% ($374.8) | Rel Volume | 0.72 | Prev Close | $384.4 |
| Employees | 7450 | LT Debt/Eq | 0.13 | EPS/Sales Surpr. | 49.92% 4.33% | SMA200 | 18.75% ($313.41) | Avg Volume(3M) | 0.25M | Price | $372.18 |
| IPO | 1980/2/27 | Option/Short | Yes/Yes | Trades | 6304 | Volume | 183,136 | Change | -3.18% |
🧪 This U.S. healthcare company supplies instruments, reagents, and consumables used in life sciences research and clinical diagnostics. It operates with two main pillars: research tools such as genetic analysis and protein purification, along with clinical diagnostic products including blood testing and quality control. As a life sciences tools stock, its performance is closely tied to R&D and diagnostic demand.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded less than usual. That is 72% of its average volume.
Next earnings report: November 4
4 days to go.
BIO earns at a steady pace
Of every $100 in sales, $9.08 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -1.7% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $3,632. Peers typically go for $1,845. Compared with its own 2-year average, it is 101% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -53.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 72.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PRVS Parnassus Value Select ETF 0.02% 
MDEV First Trust Indxx Medical Devices ETF 0.02% 
CGV Conductor Global Equity Value ETF 0.02% 
HTEC ROBO Global Healthcare Technology and Innovation ETF 0.02% 
SAEF Schwab Ariel Opportunities ETF 0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
IBB iShares Biotechnology ETF 11.5B 
XBI State Street SPDR S&P Biotech ETF 10.8B 
FBT First Trust NYSE Arca Biotechnology Index Fund 3.1B 
PBPH Portfolio Building Block World Pharma and Biotech Index ETF 1.2B 
LABU Direxion Daily S&P Biotech Bull 3X ETF 673M It ranks #16 of 142 in the industry
Based on market cap of $10B.
GMED#14 Globus Medical Inc $10B PER 20.0 
PODD#15 Insulet Corp $10B PER 29.7 BIO#16 Bio-Rad Laboratories Inc $10B PER 45.1 
TXG#17 10x Genomics Inc $9B PER - 
BRKR#18 Bruker Corp $9B PER - 
FAQ
What kind of company is BIO?
BIO belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of BIO?
The market cap of BIO is approximately $10.0B, ranking 922 within its sector.
What is the P/E ratio of BIO?
BIO has a P/E ratio of approximately 45.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BIO?
BIO has recorded a 52-week high of $396.23 and a low of $236.73.
